Browsing Tag

CTX110

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT)…

Eli Pacheco Nov 22, 2021 0

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based…

Health

CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™…

Eli Pacheco Oct 13, 2021 0

-58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT)…

Health

CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data

Eli Pacheco Oct 6, 2021 0

-Management to host conference call and webcast on October 12th at 4:30 p.m. ET- ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:…